Search results
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Benzinga via Yahoo Finance· 2 years agoExelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial...
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced detailed results from the ongoing phase III study, COSMIC-313. The...
Advanced Esophageal Cancer and Immunotherapy
Verywell Health via Yahoo News· 9 months agoA Newer Treatment OptionMedically reviewed by Gagandeep Brar, MD Immunotherapy for esophageal cancer is a newer treatment approach shown to improve the...
New cell-based therapy for melanoma more effective than existing treatment, trial finds
NBC News via Yahoo News· 2 years agoEuropean researchers announced Saturday that a new treatment for advanced melanoma was more...
Promising melanoma therapy could be the next major advancement in cancer treatment
NBC News via Yahoo News· 1 year agoAn experimental treatment for advanced melanoma is poised to be the next major advance in cancer...
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 2 weeks agoBristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab)...
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney...
Benzinga via Yahoo Finance· 4 months agoBristol Myers Squibb & Co (NYSE:BMY) announced that Opdivo (nivolumab) plus Yervoy (ipilimumab)...
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Exelixis (EXEL). Shares have lost about 8.8%...
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
Zacks via Yahoo Finance· 2 years agoThe biotech sector was in focus this past week with important regulatory and pipeline updates on key...
TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study
Benzinga via Yahoo Finance· 1 year agoTRACON Pharmaceuticals Inc (NASDAQ: TCON) announced the IDMC for the ongoing ENVASARC Phase 2...